AU2014223679B2 - Treatment of central nervous system disorders by intranasal administration of immunoglobulin G - Google Patents

Treatment of central nervous system disorders by intranasal administration of immunoglobulin G Download PDF

Info

Publication number
AU2014223679B2
AU2014223679B2 AU2014223679A AU2014223679A AU2014223679B2 AU 2014223679 B2 AU2014223679 B2 AU 2014223679B2 AU 2014223679 A AU2014223679 A AU 2014223679A AU 2014223679 A AU2014223679 A AU 2014223679A AU 2014223679 B2 AU2014223679 B2 AU 2014223679B2
Authority
AU
Australia
Prior art keywords
disorder
igg
subject
pooled human
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014223679A
Other languages
English (en)
Other versions
AU2014223679A1 (en
Inventor
William H. Frey
Leah Ranae Bresin Hanson
Sharon Pokropinski
Francisco M. Rausa Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2014223679A1 publication Critical patent/AU2014223679A1/en
Priority to AU2018260883A priority Critical patent/AU2018260883B2/en
Application granted granted Critical
Publication of AU2014223679B2 publication Critical patent/AU2014223679B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: Baxalta GmbH, BAXALTA INCORPORATED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
AU2014223679A 2013-02-26 2014-02-25 Treatment of central nervous system disorders by intranasal administration of immunoglobulin G Active AU2014223679B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018260883A AU2018260883B2 (en) 2013-02-26 2018-11-08 Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361769673P 2013-02-26 2013-02-26
US61/769,673 2013-02-26
US201361862814P 2013-08-06 2013-08-06
US61/862,814 2013-08-06
PCT/US2014/018426 WO2014134070A1 (en) 2013-02-26 2014-02-25 Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018260883A Division AU2018260883B2 (en) 2013-02-26 2018-11-08 Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

Publications (2)

Publication Number Publication Date
AU2014223679A1 AU2014223679A1 (en) 2015-09-24
AU2014223679B2 true AU2014223679B2 (en) 2018-11-29

Family

ID=50424697

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014223679A Active AU2014223679B2 (en) 2013-02-26 2014-02-25 Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
AU2018260883A Expired - Fee Related AU2018260883B2 (en) 2013-02-26 2018-11-08 Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018260883A Expired - Fee Related AU2018260883B2 (en) 2013-02-26 2018-11-08 Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

Country Status (13)

Country Link
US (5) US9556260B2 (https=)
EP (2) EP2961426B1 (https=)
JP (1) JP6379113B2 (https=)
AU (2) AU2014223679B2 (https=)
DK (1) DK2961426T3 (https=)
ES (1) ES2759226T3 (https=)
HR (1) HRP20192111T1 (https=)
HU (1) HUE046752T2 (https=)
LT (1) LT2961426T (https=)
PL (1) PL2961426T3 (https=)
PT (1) PT2961426T (https=)
SI (1) SI2961426T1 (https=)
WO (1) WO2014134070A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150100042A1 (en) * 2013-10-07 2015-04-09 Impel Neuropharma Inc. Muroid Family Nasal Device
EP3129013A1 (en) * 2014-04-10 2017-02-15 Crowley, Patrick Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
US11331270B2 (en) 2017-08-20 2022-05-17 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2020163815A1 (en) * 2019-02-07 2020-08-13 Innomed Technologies, Inc. Ivig treatments for bell's palsy
WO2020263484A1 (en) * 2019-06-28 2020-12-30 Mayo Foundation For Medical Education And Research Methods and materials for treating neuromyelitis optica spectrum diseases
KR20220047332A (ko) * 2019-08-13 2022-04-15 알티뮨 인크. 치료제 효과 및 이의 투여 경로
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
EP3991573A1 (de) * 2020-11-03 2022-05-04 Patrick Faber Zusammensetzungen zur nasalen applikation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095616A2 (en) * 2006-02-15 2007-08-23 Ramot At Tel Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2007106617A2 (en) * 2006-01-30 2007-09-20 Talecris Biotherapeutics, Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using igm
US20070254889A1 (en) * 2001-04-23 2007-11-01 Lee-Way Jin Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease
WO2009111240A1 (en) * 2008-02-29 2009-09-11 Baxter International Inc. ANTI-AMYLOID β ACTIVITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN VITRO
WO2011095543A1 (en) * 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (https=) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
KR100390480B1 (ko) 1995-01-23 2003-10-04 디렉트-할러 아/에스 흡입기
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
CA2462682A1 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. The use of gammaglobulin for the treatment of immune-mediated diseases
US20040101909A1 (en) 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
NZ581205A (en) 2005-02-23 2011-06-30 Alza Corp Intranasal administration of active agents to the central nervous system
US9084777B2 (en) * 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
EP2152240A4 (en) 2007-06-08 2012-05-09 Healthpartners Res Foundation PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
WO2011150284A2 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254889A1 (en) * 2001-04-23 2007-11-01 Lee-Way Jin Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease
WO2007106617A2 (en) * 2006-01-30 2007-09-20 Talecris Biotherapeutics, Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using igm
WO2007095616A2 (en) * 2006-02-15 2007-08-23 Ramot At Tel Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2009111240A1 (en) * 2008-02-29 2009-09-11 Baxter International Inc. ANTI-AMYLOID β ACTIVITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN VITRO
WO2011095543A1 (en) * 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOLLI R ET AL, "l-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions", BIOLOGICALS, vol. 38, no. 1, (2010-01-01), pages 150 - 157, (2010-03-06) *
DODEL RICHARD ET AL, LANCET NEUROLOGY MAR 2013, (2013-01-31), vol. 12, no. 3, pages 233 - 243 *
Fu et al., "Amyloid-[beta] Immunotherapy for Alzheimer's Disease", April 2010, CNS Neurological Disorders - Drug Targets, Vol. 9, No. 2, Pages 197-206. *
H. FILLIT ET AL, "IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders", NEUROLOGY, (2009-07-20), vol. 73, no. 3, doi:10.1212/WNL.0b013e3181ae7aaf, ISSN 0028-3878, pages 180 - 185 *
Magga et al. "Human intravenous immunoglobulin provides protection against Ab toxicity by multiple mechanisms in a mouse model of Alzheimer’s disease", J Neuroinflam., 7:90, 2010. *
St-Amour et al., "Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson’s disease", J Neuroinflammation, 9:234, 2012. *
SUSANN CATTEPOEL ET AL,PLOS ONE, (2011-04-05), vol. 6, no. 4, page e18296 *

Also Published As

Publication number Publication date
US20140242067A1 (en) 2014-08-28
JP6379113B2 (ja) 2018-08-22
ES2759226T3 (es) 2020-05-08
EP3597220A1 (en) 2020-01-22
PT2961426T (pt) 2019-12-09
LT2961426T (lt) 2019-12-27
US12503501B2 (en) 2025-12-23
EP2961426B1 (en) 2019-10-30
AU2014223679A1 (en) 2015-09-24
SI2961426T1 (sl) 2020-01-31
DK2961426T3 (da) 2019-12-02
AU2018260883B2 (en) 2020-08-06
US9556260B2 (en) 2017-01-31
JP2016512490A (ja) 2016-04-28
EP2961426A1 (en) 2016-01-06
HUE046752T2 (hu) 2020-03-30
US20190055307A1 (en) 2019-02-21
AU2018260883A1 (en) 2018-11-29
HRP20192111T1 (hr) 2020-03-20
US11851481B2 (en) 2023-12-26
US20240117025A1 (en) 2024-04-11
WO2014134070A1 (en) 2014-09-04
US10144776B2 (en) 2018-12-04
US20210101967A1 (en) 2021-04-08
US20170044244A1 (en) 2017-02-16
PL2961426T3 (pl) 2020-02-28

Similar Documents

Publication Publication Date Title
US12503501B2 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
AU2019202459B2 (en) Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
AU2006227528B2 (en) Use of ADNF polypeptides for treating peripheral neurotoxicity
AU2020348916B2 (en) Detection of antibodies against RAN proteins from serum and tissue lysates
AU2021200093B2 (en) Treatment and prevention of alzheimer's disease (ad)
AU2024202756A1 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
JP7610767B2 (ja) レット症候群の処置のためのセマフォリン４ｄ結合分子の使用
JP2020530846A (ja) 方法
US11541086B2 (en) Compositions and methods for treating Alzheimer's disease
HK40015677A (en) Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): BAXALTA GMBH; BAXALTA INCORPORATED